Correlation Engine 2.0
Clear Search sequence regions
Bookmark Forward

QuickView for Doxazosin (compound)


PubChem
Name: Doxazosin
PubChem Compound ID: 3157
Description: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
Molecular formula: C23H25N5O5
Molecular weight: 451.475 g/mol
Synonyms:
Doxazosine [French]; 1-(4-Amino-6,7-Dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin; Doxazosin; ChemDiv2_005017; 77883-43-3; Prestwick0_000858; 74191-85-8; Doxazosinum [Latin]; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-; Doxazosina [Spanish].
show more »
DrugBank
Identification
Name: Doxazosin
Name (isomeric): DB00590
Drug Type: small molecule
Description: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
Synonyms:
Doxazosin mesilate; Doxazosin mesylate
Brand: Cardenalin, Cardular, Carduran, Alfadil, Cardura XL, Normothen, Diblocin, Supressin, Cardura-4, Cardura-2, Cardura, Cardura-1
Category: Vasodilator Agents, Antineoplastic Agents, Alpha-adrenergic Blocking Agents, Antihyperplasia Agents, Adrenergic alpha-Antagonists, Antihypertensive Agents
CAS number: 74191-85-8
Pharmacology
Indication: For treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
Pharmacology:
Doxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affin...
show more »
Mechanism of Action: Doxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Absorption: 65%
Protein binding: 98%
Biotransformation: Hepatic.
Route of elimination: On average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.
Half Life: 22 hours
Toxicity: Symptoms of overdose include hypotension. Oral LD50 is greater than 1000 mg/kg in mice and rats.
Affected organisms: Humans and other mammals
Interactions
Food interaction:
Avoid alcohol.
Take without regard to meals.
Avoid natural licorice.
Drug interaction:
VardenafilAdditive hypotensive effects of the PDE5 inhibitor, Vardenafil, and alpha1-blocker, Doxazosin, may occur. Monitor for hypotension during concomitant therapy.
TamsulosinConcomitant use of alpha1-adrenergic antagonists, Tamsulosin and Doxazosin, may result in additive antihypertensive effects. Combination therapy is not recommended.
TadalafilTadalafil may enhance the hypotensive effect of Doxazosin. Monitor for hypotension during concomitant therapy.
TreprostinilAdditive hypotensive effect. Monitor antihypertensive therapy during concomitant use.

Targets


Enzymes


Transporters


Carriers